Cell therapy company Chimeric Therapeutics (ASX:CHM) has announced that the Japan Patent Office has issued a Notice of Allowance for application JP2022007016A.
The application covers certain chimeric antigen receptor (CAR) technology applications using chlorotoxin (CLTX), including Chimeric’s clinical-stage CAR T asset CHM 1101 and preclinical-stage CAR NK asset CHM 1301.
The company said initial patent protection for CLTX CAR technology in Japan was granted in 2022 under patent number JP 7,085,990.
The newly allowed application, JP2022007016A, expands the scope of patent protection to cover a broader range of CLTX CAR construct designs.
Chimeric’s CEO and managing director Jennifer Chow said, “We are delighted to see our patent protection for CLTX CAR therapies broadened in Japan, the third largest pharmaceutical market in the world, where CAR T cell therapies for blood cancers have already been successfully commercialized. The grant of this key Japan patent will further expand the robust intellectual property portfolio underpinning our CLTX CAR pipeline assets.”
